Online citations, reference lists, and bibliographies.

The Anti-cancer Drug Lenalidomide Inhibits Angiogenesis And Metastasis Via Multiple Inhibitory Effects On Endothelial Cell Function In Normoxic And Hypoxic Conditions.

Ling Lu, Faribourz Payvandi, Lei Wu, Li Zhang, Robert J. Hariri, Ho Kai Man, Roger Shen-Chu Chen, George W. Muller, Christopher C. W. Hughes, David I. Stirling, Peter H. Schafer, Justin Blake Bartlett
Published 2009 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K-Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1 alpha expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide in vivo was confirmed in the B16-F10 mouse melanoma model by a >40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug.
This paper references
10.1038/nature04871
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouyssegur (2006)
10.1073/pnas.242590799
Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion
Noriyuki Kataoka (2002)
10.1182/blood.V106.11.372.372
Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.
Guntram Büsche (2005)
10.1161/01.RES.0000022200.71892.9F
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Ichiro Shiojima (2002)
10.1182/blood-2006-04-015909
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Paul G Richardson (2006)
10.1073/pnas.91.9.4082
Thalidomide is an inhibitor of angiogenesis.
Robert J D'Amato (1994)
10.1016/j.mvr.2005.01.002
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Keith Dredge (2005)
10.1038/nrc905
Clinical translation of angiogenesis inhibitors
Robert S. Kerbel (2002)
10.1038/sj.bjc.6600607
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
Keith Dredge (2002)
10.1111/j.0959-9673.2004.00396.x
Current methods for assaying angiogenesis in vitro and in vivo.
Carolyn A. Staton (2004)
Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin.
Takeshi Matsumura (1997)
10.1038/nrc704
Hypoxia — a key regulatory factor in tumour growth
Adrian L. Harris (2002)
10.1056/NEJMoa061292
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F List (2006)
10.1158/0008-5472.CAN-06-2056
Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies.
Philippe Martinive (2006)
10.1097/00001622-200001000-00015
Is angiogenesis inhibition the Holy Grail of cancer therapy?
T Boehm-Viswanathan (2000)
10.1124/mol.64.5.1029
Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
Ming-Tsan Lin (2003)
10.1158/0008-5472.CAN-03-2239
Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis
Andrew M Arsham (2004)
10.1038/nrc1323
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Blake Bartlett (2004)
10.1182/blood-2005-09-3541
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.
Maura Calvani (2006)
10.1038/35025220
Angiogenesis in cancer and other diseases
Peter Carmeliet (2000)
10.1074/jbc.M300763200
Regulation of Hypoxia-inducible Factor-1α Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Pathway in HepG2 Cells*
Denis Mottet (2003)
10.1016/S1535-6108(03)00336-2
Antiangiogenic therapy and tumor progression.
Mikhail V. Blagosklonny (2004)
10.1158/0008-5472.CAN-06-2701
Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression
Debbie Liao (2007)
10.1128/MCB.23.16.5726-5737.2003
Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase Akt Pathway Mediates Nitric Oxide-Induced Endothelial Cell Migration and Angiogenesis
Koh Kawasaki (2003)
10.1016/S0092-8674(00)81683-9
The Hallmarks of Cancer
Douglas Hanahan (2000)



This paper is referenced by
alidomide in Nonmetastatic Biochemically Relapsed state Cancer: Results of a Phase I/II
Len Pro Dou (2010)
10.1002/ijc.32125
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Evangelos Terpos (2019)
10.1016/j.yexcr.2014.09.018
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Enrica Borsi (2014)
10.1634/theoncologist.2014-0073
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Zahra Hanaizi (2015)
10.1155/2010/185687
Angiogenesis and Progression in Human Melanoma
Roberto Ria (2010)
10.1186/s12967-016-0872-2
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
Valeria Leuci (2016)
10.4264/NUMA.76.1_19
Immunomodulatory Effects of Small-Molecule Compounds: Impact on Hematologic Malignancies
Noriyoshi Iriyama (2017)
10.1007/978-1-4939-1176-9_19
Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
Petros D. Grivas (2014)
10.1016/S0268-960X(10)70004-7
Lenalidomide mode of action: linking bench and clinical findings.
Faith Davies (2010)
10.3390/ijms19061551
Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy
Manon Bosseler (2018)
10.1007/s00262-014-1610-3
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa (2014)
10.1016/j.clgc.2013.09.001
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Chadi Nabhan (2014)
10.1111/ejh.12352
Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
Jiang-Hua Ding (2014)
10.1073/pnas.1307684110
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
Chris Mahony (2013)
10.1007/s00262-014-1571-6
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
Brenda De Keersmaecker (2014)
10.1016/j.ceb.2015.10.004
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Andrew A Guirguis (2015)
10.1016/j.exphem.2013.10.007
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Rossana Maffei (2014)
10.1073/PNAS.1318475110
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos
Neil Vargesson (2013)
10.1093/abbs/gmt142
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.
Xiubao Chang (2014)
10.1016/j.pharmthera.2012.01.001
A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.
Anna I Astashkina (2012)
10.1038/leu.2012.119
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
Antonia Lopez-Girona (2012)
10.2741/4209
Bone marrow vascular niche and the control of angiogenesis in multiple myeloma.
Domenico Ribatti (2014)
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide Rand S-Enantiomers
Yan Li (2014)
10.1517/14740338.2016.1154039
The safety of pomalidomide for the treatment of multiple myeloma
John Rhys Jones (2016)
10.1063/1.4994599
A perforated microhole-based microfluidic device for improving sprouting angiogenesis in vitro
Sijia Chen (2017)
10.1002/cncr.30585
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Maximilian Stahl (2017)
10.2174/1871529X18666180522073855
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Ota Fuchs (2019)
10.1007/s00262-019-02411-y
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Caterina Lapenta (2019)
10.1002/jcph.384
Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Claudia Kasserra (2015)
POMALIDOMID V LIEČBE RELABUJÚCEHO A REFRAKTÉRNEHO MNOHOPOČETNÉHO MYELÓMU
Ľubica Roziaková (2014)
10.5772/20413
Role of Angiogenesis and Microenvironment in Melanoma Progression
Roberto Ria (2011)
The Effect of Small Organic Compounds on Triple Negative Breast Cancer Cells
John D. O'Brien (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar